Table 4.
Local and Systemic Toxicity of CNTs in vitro and in vivo
S. No | Type of CNTs, Dimensions and Dose | Route of Administration | Cell Line or Animal Model | Effects or Outcomes | Ref. |
---|---|---|---|---|---|
1. | MWCNTs, lengths of 3.86 μm and diameters of 49 ±13.4 nm, 1.2 μg/mL | – | Co-cultured SAEC and HMVECs |
|
[64] |
2. | MWCNTs, lengths of 1.12 μm and diameters of 65 to 70 nm | Pharyngeal aspiration | 44 μg/mL in vitro BEAS-2B cells and 50 μL in vivo in C57BL/6 mice |
|
[65] |
3. | MWCNTs, 20 to 50 μm | Non-surgical intratracheal instillation | 30 µg/mL in vitro NIH 3T3 cells, 0.6 mg/ hypertensive rat in vivo |
|
[66,67] |
4. | MWCNTs, lengths of 5 to 13 μm and diameters of 30 to 100 nm | Pharyngeal aspiration | 1 mg/mL per 20 gm body weight of female C57Bl6/J mice | Upregulated expressions of MCP-1, MMP-8 and TIMP-1, changes in serum markers, hyperplasia and formation of granulomas | [70] |
5. | SWCNTs, 40–80 μg/mouse | Pharyngeal aspiration | Female C57BL/6 mice |
|
[71] |
6. | SWCNTs, 0.6 mg/rat | Non-surgical intratracheal instillation | Male spontaneously hypertensive rats |
|
[72] |
7. | SWCNTs, diameters of 1.2 to 1.5 nm and lengths of 2 to 5 µm, 0.16, 1.6 and 6.4 mg/kg | Intravenously into tail vein | MITO-Luc and CD1 mice |
|
[73] |